Daigneault Alessandra's Form 4 filing
NRX Pharmaceuticals, Inc. (NRXP) · filed Nov 2, 2021
- Accession no.
- 0000950142-21-003504
- Filed
- Nov 2, 2021
- Trade date
- Aug 19-Sep 2, 2021
- Filing delay
- 75 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 6 derivative transactions. Open-market sales total $442.0K. It was filed 75 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Daigneault AlessandraCIK 0001864648 | Officer (General Counsel & Secretary) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 19, 2021 | Common Stock | MOption exerciseAcquired | +27,395 | $3.07 | +$84,102.65 | 33,715 | Direct | |
| Aug 23, 2021 | Common Stock | SSaleDisposed | −33,715 | $13.11 | −$442,003.65 | 0 | Direct | |
| Sep 2, 2021 | Common Stock | MOption exerciseAcquired | +18,420 | $3.07 | +$56,549.4 | 18,420 | Direct | |
| Sep 2, 2021 | Common Stock | MOption exerciseAcquired | +13,164 | $3.07 | +$40,413.48 | 31,584 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 19, 2021 | Common Stock | CConversionDisposed | −43,000 | $3.07 | −$132,010 | 100,840 | Direct | |
| Aug 19, 2021 | Common Stock | AGrant or awardAcquired | +15,605 | $0.00 | $0 | 15,605 | Direct | |
| Sep 2, 2021 | Common Stock | CConversionDisposed | −28,916 | $3.07 | −$88,772.12 | 71,924 | Direct | |
| Sep 2, 2021 | Common Stock | CConversionDisposed | −20,666 | $3.07 | −$63,444.62 | 28,934 | Direct | |
| Sep 2, 2021 | Common Stock | AGrant or awardAcquired | +10,496 | $0.00 | $0 | 26,101 | Direct | |
| Sep 2, 2021 | Common Stock | AGrant or awardAcquired | +7,502 | $0.00 | $0 | 33,603 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.